drugset

drugset / Trial / NCT01610934

The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)

NCT01610934 ↗

Phase 2/3 Completed 15 enrolled University Hospital, Gentofte, Copenhagen Novo Nordisk A/S · collab University of Copenhagen · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the treatment potential of GLP-1-analogues in patients with Maturity Onset Diabetes of the Young (MODY) compared to common treatment.

Timeline

Start: 2012-08
Primary completion: 2013-08
Completion: 2013-08

Publications

Ostoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsboll T. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014 Jul;37(7):1797-805. doi: 10.2337/dc13-3007.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Glimepiride	Small molecule	3 mg	—
Comparator	Glimepiride	Small molecule	4 mg	—
Subject	Liraglutide	Peptide	1.2 mg	Other
Subject	Liraglutide	Peptide	1.8 mg	Other

Indications